INTRODUCTION {#s1}
============

Lung cancer is the leading cause of cancer death worldwide and its 5-year relative survival rate is low \[[@R1]\]. Traditionally, it is classified into two major subtypes, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The latter can be subdivided into adenocarcinoma (ADC), squamous cell carcinoma (SCC), and large cell carcinoma (LCC) \[[@R2]\].

In recent years, some activated oncogenes such as Epidermal Growth Factor Receptor (EGFR) mutations and Anaplastic Lymphoma Kinase (ALK) rearrangements have been found and used as novel therapeutic targets \[[@R3]--[@R5]\]. All these progresses encourage the researchers to identify new biomarkers or therapeutic targets. Of which, the cancer stem cell markers such as SRY (sex determining region Y)-box 2 (*SOX2*) and *Nestin* have gotten researchers interested.

*SOX2* locates on chromosome 3q26.33 and encodes a transcription factor of 317 amino acids \[[@R6], [@R7]\]. It has been reported to be involved in pluripotency regulation in embryonic stem cells and the morphogenesis and homoeostasis of tracheobronchial epithelia \[[@R8]\]. Recently, *SOX2* aberrant DNA amplification and protein expression have been found in various types of tumors. Functional experiments suggest that *SOX2* is responsible for cellular proliferation, tumor invasion and migration, self-renewal, maintenance in cancer stem cell populations, and lung tumorigenesis \[[@R6], [@R9]--[@R12]\]. It also has been reported that DNA amplification and protein expression of *SOX2* are associated with clinicopathological features and prognosis in lung cancers, however, the results are not always consistent \[[@R13]--[@R16]\]. Although a meta-analysis in the year of 2013 has been performed to summarize the associations, the included studies were relatively rare and the authors do not distinguish *SOX2* DNA amplification, mRNA expression, and protein expression \[[@R17]\].

*Nestin* is a member of the intermediate filament (IF) family and serves as a potential proliferative and muti-potency marker in progenitor and stem cells \[[@R18], [@R19]\]. *Nestin* has been also found to have an anti-apoptotic function through inhibiting caspase activation \[[@R20]\]. Recent observations have revealed a link between *Nestin* aberrant expression and malignant characteristics and poor prognosis in different cancers \[[@R21]--[@R25]\].

In the present study, we performed a systematic review and meta-analysis to investigate the associations of DNA amplification and protein expression of *SOX2* and *Nestin* with clinicopathological features and overall survival in NSCLC.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

The literature selection process was shown in Figure [1](#F1){ref-type="fig"}. Four English databases were used and a total of 1442 documents were initially identified. After excluding those duplicated records, animal experiments or cellular studies, non-NSCLC related studies, and non-original articles, 36 full texts were left for further evaluation. Subsequently, six articles were excluded due to insufficient data \[[@R26]--[@R31]\], and one was excluded because it contained other type of lung cancer besides NSCLC \[[@R32]\]. Here, we only focused on DNA amplification and protein expression. Then another four studies were excluded due to only reporting the *SOX2* or *Nestin* mRNA related data \[[@R33]--[@R36]\]. Finally, 25 papers were included in the present study \[[@R13]--[@R16], [@R21], [@R37]--[@R56]\]. Of which, 19 articles reported *SOX2* DNA amplification and/or protein expression \[[@R13]--[@R16], [@R37]--[@R51]\], six articles reported *Nestin* protein expression, and none reported *Nestin* DNA amplification \[[@R21], [@R52]--[@R56]\]. In addition, Velcheti et al. \[[@R46]\] and Iijima et al. \[[@R50]\] reported two independent cohorts, respectively, and each cohort was considered as independent study in the meta-analysis. The included studies were published from 2010 to 2015 and the sample size ranged from 33 to 758. In the original studies, the DNA amplification was determined by PCR or FISH (*n* = 3 and 6) and the protein expression was determined by IHC or IF (*n* = 19 and 2). The detailed characteristics of the included studies were shown in Table [1](#T1){ref-type="table"}.

![Flow chart of study selection](oncotarget-07-34520-g001){#F1}

###### Characteristics of the included studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference               Country           Patient No.   Age (year)     Method   Cut-off value                                                 Protein/\       Positive/\
                                                                                                                                                Amplification   Negative
  ----------------------- ----------------- ------------- -------------- -------- ------------------------------------------------------------- --------------- ------------
  **SOX2**                                                                                                                                                      

  Yuan et al. 2010        USA               57                           IHC      SCC (high \> 270, low \< 140); ADC (high \> 193, low \< 10)   Protein         37/19

  Yuan et al. 2010        USA               57                           qPCR     4 copy                                                        Amplification   8/49

  Lu et al. 2010          USA               40                           IHC      5%                                                            Protein         19/21

  Sholl et al. 2010       USA               104           68(36--91)     IHC      5%                                                            Protein         52/52

  Sholl et al. 2010       USA               66                           IHC      5%                                                            Protein         41/25

  Wilbertz et al. 2011    Switzerland/USA   758                          FISH     30%                                                           Amplification   224/534

  Cai et al. 2011         China             115           58(27--77)     PCR      Ratio \> M + 2SD                                              Amplification   30/85

  Cai et al. 2011         China             150           58(27--77)     IHC      5%                                                            Protein         79/71

  Koji et al. 2011        Japan             309                          IHC      5%                                                            Protein         

  Sasaki et al. 2012      Japan             127           66.0 ± 10.2    PCR      4 copy                                                        Amplification   42/85

  Brcic et al. 2012       American          147                          IHC      5%                                                            Protein         14/52

  Brcic et al. 2012       American          147                          FISH     CN/chrom \> 2                                                 Amplification   18/52

  Li et al. 2012          China             44                           IHC      10%                                                           Protein         31/13

  Chen et al. 2012        China             381                          IHC      10%                                                           Protein         374/7

  Velcheti et al. 2013    Greek             340           62.32 ± 9.04   IF       Score \> 193                                                  Protein         418/229

  Velcheti et al. 2013    USA               307           65.17 ± 9.92   IF       Score \> 193                                                  Protein         

  Chou et al. 2013        China             175                          IHC      No stain in nuclear                                           Protein         51/124

  Yusuke et al. 2015      Japan             282           67(33--86)     FISH     Mean value                                                    Amplification   34/244

  Toschi et al. 2015      Italy             447                          FISH     4 copy or presence of gene cluster                            Amplification   105/340

  Yoon et al. 2015        Korea             33            66(48--73)     IHC      Internal control                                              Protein         22/11

  Yoon et al. 2015        Korea             33            66(48--73)     FISH     10 green signal                                               Amplification   26/7

  Iijima et al. 2015      China cohort      57                           IHC      H-score \> 0                                                  Protein         40/17

  Iijima et al. 2015      Japan cohort      66                           IHC      H-score \> 0                                                  Protein         45/21

  Zheng et al. 2015       China             162           61.6(40--88)   IHC      100 score                                                     Protein         85/65

  Zheng et al. 2015       China             162           61.6(40--88)   FISH     4 gene copy                                                   Amplification   50/61

  **Nestin**                                                                                                                                                    

  Chen et al. 2010        China             52            58.2 ± 10.0    IHC      8.4(median histoscore of *Nestin*)                            Protein         25/27

  Janikova et al. 2010    Czech             121                          IHC      10%                                                           Protein         74/38

  Ryuge et al. 2011       Japan             173           64(34--85)     IHC      5%                                                            Protein         27/144

  Skarda et al. 2012      Czech & Israel    115           60.3           IHC      H-score \> 0                                                  Protein         40/74

  Chen et al. 2014        China             71            57.6 ± 9.8     IHC      8.4(median histoscore of Nestin)                              Protein         35/36

  Sterlacci et al. 2014   Austria           215                          IHC      Median % positive staining cell                               Protein         57/269
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Meta-analysis results {#s2_2}
---------------------

SOX2 {#s2_3}
----

Significant associations were identified between high/positive *SOX2* DNA amplification and clinicopathological features, gender (OR = 1.969, 95% CI = 1.050--3.693, *P* = 0.035), smoking status (OR = 2.830, 95% CI = 1.269--6.310, *P* = 0.011), histology (OR = 8.136, 95% CI = 2.136--30.997, *P* = 0.000), differentiation (OR = 1.644, 95% CI = 1.119--2.415, *P* = 0.011), and OS (HR = 0.732, 95% CI = 0.593--0.904, *P* = 0.004) (Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). For *SOX2* protein expression, *i*ts associations with smoking status (OR = 2.245, 95% CI = 1.008-- 5.001, *P* = 0.048), histology (OR = 5.437, 95% CI = 2.344-- 12.610, *P* = 0.000), and OS (HR = 0.579, 95% CI = 0.359--0.934, *P* = 0.025) were found (Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}).

![Forest plot for associations of *SOX2* with clinicopathological features and overall survival in NSCLC](oncotarget-07-34520-g002){#F2}

###### Meta-analysis results

  Clinical parameters                          *N*   OR/HR        OR/HR95%CI          *P~OR~*     Model   *I*^2^     *P~hetero~*   *P~Eegg~*   *P~Egger~*
  -------------------------------------------- ----- ------------ ------------------- ----------- ------- ---------- ------------- ----------- ------------
  **SOX2 Amplification**                                                                                                                       
  Gender(male vs. female)                      8     **1.969**    **1.050--3.693**    **0.035**   R       **55.6**   **0.027**     0.711       0.652
  Age (≤ 60 vs. \> 60 or ≤ 65 vs. \> 65)       3     0.857        0.507--1.448        0.563       F       0.6        0.365         1.000       0.367
  Smoking status (yes vs. no)                  7     **2.830**    **1.269--6.310**    **0.011**   R       **62.2**   **0.014**     0.368       0.052
  Histology (SCC vs. ADC)                      6     **16.530**   **5.134--53.221**   **0.000**   R       **89.7**   **0.000**     0.707       0.885
  Differentiation (moderate+poor vs. well)     5     **1.644**    **1.119--2.415**    **0.011**   F       0.0        0.935         0.462       0.629
  Differentiation (poor vs. well+moderate)     3     0.807        0.317--2.054        0.654       R       **68.2**   **0.041**     1.000       0.796
  Lymph node metastasis (N~0~ vs. N~1--3~)     5     0.943        0.678--1.312        0.728       F       0.0        0.650         0.806       0.688
  Lymph nodemetastasis (N~0--1~ vs. N~2--3~)   3     0.903        0.468--1.743        0.761       F       0.0        0.418         0.308       0.168
  Stage (I vs. II--IV)                         5     1.222        0.860--1.737        0.263       F       0.0        0.855         0.221       0.363
  Stage (I--II vs. III--IV)                    4     1.226        0.877--1.714        0.232       F       0.0        0.849         0.734       0.690
  OS                                           6     **0.732**    0.593--0.904        **0.004**   F       0.0        0.949         0.707       0.794
  **SOX2 Protein expression**                                                                                                                  
  Gender(male vs. female)                      9     1.345        0.726--2.493        0.558       R       **55.1**   **0.023**     0.917       0.738
  Age (≤ 60 vs. \> 60 or ≤65 vs. \> 65)        6     0.439        0.104--1.857        0.263       R       **90.3**   **0.000**     0.368       0.199
  Smoking status (yes vs. no)                  5     **2.245**    1.008--5.001        **0.048**   R       **58.9**   **0.045**     0.806       0.537
  Histology (SCC vs. ADC)                      7     **5.437**    2.344--12.610       **0.000**   R       **68.7**   **0.004**     1.000       0.749
  Differentiation (moderate+poor vs. well)     6     1.082        0.695--1.685        0.726       F       0.0        0.694         1.000       0.471
  Differentiation (poor vs. well+moderate)     9     0.723        0.517--1.011        0.058       F       14.2       0.316         1.000       0.496
  Lymph node metastasis (N~0~ vs. N~1-3~)      3     1.078        0.649--1.789        0.772       F       0.0        0.693         1.000       0.952
  Lymph nodemetastasis (N~0-1~ vs. N~2-3~)     1                                                                                               
  Stage (I vs. II--IV)                         4     1.288        0.807--2.057        0.289       F       18.4       0.298         0.734       0.959
  Stage (I--II vs. III--IV)                    3     0.818        0.327--2.044        0.667       F       5.3        0.348         1.000       0.648
  OS                                           9     0.579        0.359--0.934        **0.025**   R       **84.9**   **0.000**     0.466       0.109
  **Nestin Protein expression**                                                                                                                
  Gender (male vs. female)                     4     0.932        0.569--1.527        0.780       F       11.7       0.334         0.734       0.478
  Age (≤ 60 vs. \> 60 or ≤ 65 vs. \> 65)       3     1.111        0.650--1.897        0.701       F       5.1        0.349         0.294       0.174
  Smoking status (yes vs. no)                  3     1.237        0.486--3.151        0.655       R       **60.7**   **0.078**     1.000       0.145
  Histology (SCC vs. ADC)                      4     2.378        0.420--13.462       0.327       R       **92.0**   **0.000**     0.734       0.542
  Differentiation (well+moderate vs. poor)     3     2.671        0.170--41.861       0.484       R       **94.6**   **0.000**     1.000       0.335
  Lymph node metastasis (N~1--3~ vs. N~0~)     2     **2.732**    **1.393--5.376**    **0.004**   F       0.0        0.694                     
  Stage (II--IV vs. I)                         3     **1.996**    **1.157--3.445**    **0.013**   F       0.0        0.981         1.000       0.534
  OS                                           5     **2.166**    **1.437--3.263**    **0.000**   R       **68.4**   **0.013**     0.806       0.534

Nestin {#s2_4}
------

There was no study reporting *Nestin* DNA amplification in NSCLC and then only *Nestin* protein expression was analyzed. The pooling analyses revealed significant associations of *Nestin* protein expression with lymph node matastasis (OR = 2.732, 95% CI = 1.393-- 5.376, *P* = 0.004), stage (OR = 1.996, 95% CI = 1.157--3.445, *P* = 0.013), and OS (HR = 2.166, 95% CI = 1.437--3.263, *P* = 0.000) (Figure [3](#F3){ref-type="fig"} and Table [2](#T2){ref-type="table"}).

![Forest plot for associations of *Nestin* with clinicopathological features and overall survival in NSCLC](oncotarget-07-34520-g003){#F3}

Heterogeneity and sensitivity analysis {#s2_5}
--------------------------------------

SOX2 {#s2_6}
----

The heterogeneity and sensitivity were analyzed by subgroup analysis according to ethnicity, histology, and sample size or excluding single individual study. The results indicated that the heterogeneity existed in evaluating the associations of *SOX2* DNA amplification with gender (*I*^2^ = 55.6%), smoking status (*I*^2^ = 62.2%), histology (I^2^ = 89.7%), and differentiation (poor vs. well+moderate, *I*^2^ = 68.2%) (Table [2](#T2){ref-type="table"}). For gender, heterogeneity decreased to 31.4% after excluding Wilbertz et al\'s study and the pooling OR was not influenced. For smoking status, after grouping by China and non-China studies, heterogeneity of both subgroups decreased to 0% and the associations were still significant. For histology, the heterogeneity could not be removed by subgroup analyses or excluding single individual study. For differentiation, the heterogeneity deceased (*I*^2^ = 19.3%) by excluding the study of Zhang et al. 2015 and the pooling OR was not influenced. Meanwhile, there were significant heterogeneity in assessment of the associations of *SOX2* protein expression with gender (*I*^2^ = 55.1%), age (*I*^2^ = 90.3%), smoking status (*I*^2^ = 58.9%), histology (*I*^2^ = 68.7%), and OS (*I*^2^ = 84.9%). The heterogeneity deceased significantly when deleting single individual studies of Chou et al. 2013 (gender, *I*^2^ = 38.7%), Chen et al. 2012 (age, *I*^2^ = 15.0%), Zheng et al. 2015 (smoking status, *I*^2^ = 0%), and Li et al. 2012 (histology, *I*^2^ = 34.5%), respectively. And the pooled ORs were not influenced, suggesting the results were stable. For OS, the heterogeneity still existed when excluding single individual study one by one. In subgroup analysis stratified by histology (SCC, *n* = 4; ADC, *n* = 1; and SCC/ADC, *n* = 4), heterogeneity was 29.7% in SCC, and 90.3% in SCC/ADC. And the association was significant in SCC but not SCC/ADC.

Nestin {#s2_7}
------

As shown in Table [2](#T2){ref-type="table"}, there was heterogeneity in assessment of the associations of *Nestin* protein expression with smoking status (*I*^2^ = 60.7%), histology (*I*^2^ = 92.0%), differentiation (*I*^2^ = 94.6%), and OS (I^2^ = 68.4%). When the studies of Chen et al. 2010, Ryuge et al. 2011, and Janikova et al. 2012 were excluded, respectively, the heterogeneity significantly decreased (smoking status, *I*^2^ = 0%; differentiation, *I*^2^ = 0%; and OS, *I*^2^ = 48.2%) and the pooling ORs were not influenced except differentiation. As for histology, subgroup analysis suggested that the heterogeneity among the studies performed in China was decreased (*I*^2^ = 0%) and a significant association was presented. But the heterogeneity still existed in Japan group (*I*^2^ = 95.5%).

Publication bias {#s2_8}
----------------

Furthermore, publication bias was also assessed by Begg\'s test and Egger\'s test. Symmetrical Begg\'s funnel plots and Egger\'s test results revealed no publication bias in all comparisons (Figure [4](#F4){ref-type="fig"} and Table [2](#T2){ref-type="table"}).

![Begg\'s funnel plot for publication bias analysis](oncotarget-07-34520-g004){#F4}

DISCUSSION {#s3}
==========

A number of studies have been performed to explore the associations of cancer cell stem cell markers, such as *SOX2* and *Nestin*, with clinical parameters and prognosis in various types of cancers including NSCLC. However, the results in the studies were not consistent.

Up to now, there were two meta-analyses tying to investigate the associations of *SOX2* with clinicopathological features and/or overall survival in NSCLC \[[@R17], [@R57]\]. Chen et al. \[[@R17]\] only searched relevant studies in PubMed, up to May 2013 and included eight studies. Shao et al. \[[@R57]\] pooled seven studies published from 2010 to 2013. Neither of the studies distinguished *SOX2* DNA amplification, mRNA expression, and protein expression. In the present study, we analyzed *SOX2* DNA amplification and protein expression, respectively, unlike with the above reports. We searched in more English database and included more articles than the previous meta-analysis (19 vs. 8 and 7) although we did not combined the mRNA related studies. Pooling analyses suggested that both of the DNA amplification and the protein expression of *SOX2* were associated with smoking status, histology, and OS. In addition, *SOX2* DNA amplification was also associated with gender and differentiation. The discrepancy between DNA amplification and protein expression might be caused by the heterogeneity among studies and the inconsistency between amplification and protein expression. More studies examining amplification and protein expression of *SOX2* at the same time should be performed to confirm the conclusions. For *Nestin*, there was only one meta-analysis examining the associations of *Nestin* protein expression with TNM in regardless of cancer types. And the authors found that *Nestin* was positively associated with cancer stage and lymph node \[[@R58]\]. In the present meta-analysis, we summarized the associations of *Nestin* with clinicopathological features and OS in a single type of cancer, NSCLC. The pooling analyses suggested that high/positive *Nestin* was an indicator of poor prognosis in NSCLC, not as well as *SOX2*, which was a favorable factor for OS in NSCLC. This might bring us confusion when understanding the role of the two genes in molecular pathogenesis of NSCLC. Because both of them were cancer stem cell markers and mechanisms studies suggested that they all had proliferative and anti-apoptotic effects *in vitro* and animal model. Combined the results of the previous reports and the present meta-analysis, we proposed a mechanism model that *SOX2* was an oncogene and promoted tumorigenesis. Meanwhile, the tumors with *SOX2* up-regulation might exhibit a clearer squamous cell differentiation and were associated with better prognosis.

Although we pooled all the potential studies according to the inclusion and exclusion criteria, some limitations existed. Firstly, the number and sample size of *Nestin* related studies were small. Secondly, the studies of the subgroup of ADC for *SOX2* were rare. As the original studies suggested that *SOX2* was more frequently upregulated in SCC than ADC, the predictive role of *SOX2* in SCC and ADC might be not consistent. Then the impact of *SOX2* on prognosis in SCC and ADC should be compared in more studies with larger sample size.

In summary, we got a comprehensive result from the current meta-analysis that *SOX2* DNA amplification and protein expression were associated with smoking status and histology, and were favorable for prognosis in NSCLC. And *Nestin* was associated with cancer stage, lymph node, and poor outcome.

MATERIALS AND METHODS {#s4}
=====================

Publication search {#s4_1}
------------------

A systematic search was performed in four English databases (PubMed, EMBASE, OVID, and Web of science) for published articles on the associations of *SOX2* and *Nestin* with clinical features and/or overall survival (OS) in NSCLC up to November 10, 2015. The following keywords were used: "lung OR pulmonary", "cancer OR tumor OR carcinoma", and "*Nestin* OR Sex determining region Y box-2 OR SRY box-2 OR *SOX2*". Two independent investigators screened the retrieved documents by reviewing the article titles, abstracts, or full texts according to the inclusion and exclusion criteria. The review articles and the references of selected articles were also screened to identify additional eligible studies.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Inclusion criteria: (1) the histologic type of the tumors was NSCLC and if one study containing multiple types of lung cancer, only the data related to NSCLC was included; (2) evaluating the associations of *SOX2* and *Nestin* DNA amplification and/or protein expression with clinicopathological features and OS; (3) peer reviewed papers that have been published as full texts; (4) the language was limited as English; (5) if mutiple studies contained overlap or duplicated data, only the study with larger sample size was included. Exclusion criteria: (1) the frequency of patients with positive/negative/high/low DNA amplification and protein expression was not specific to clinicopathological features; (2) study with insufficient data; (3) abstracts, letters, or review articles.

Data extraction {#s4_3}
---------------

Two independent investigators collected related data carefully and the following characteristics were extracted from included studies: first author name, year of publication, country, ethnicity, patient number, gender, age, protein expression/amplification, method, cut-off value, smoking status, histologic type, differentiation, lymph node metastasis, stage, and OS.

Statistical analysis {#s4_4}
--------------------

All the statistical analyses were carried out with the software Stata 12.0 (StataCorp, College Station, TX, USA). The crude odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated to estimate the associations of DNA amplification and protein expression of *SOX2* and *Nestin* with clinicopathological features of NSCLC. The crude hazard ratios (HRs) with 95%CIs were used to assess their clinical significance in predicting prognosis of NSCLC. The statistical significant level was determined by *Z*-test with *P* value less than 0.05. If the prognosis was only presented by a Kaplan-Meier plot curve, HR and its 95%CI were calculated according to previous reports \[[@R59], [@R60]\]. Briefly, the KM plot curves were read by Engauge Digitizer version 2.11 and HR was estimated by the calculation spreadsheet. The spreadsheet could be freely downloaded from <http://www.trialsjournal.com/content/supplementary/1745-6215-8-16-s1.xls>. Inconsistency was solved by discussion. The heterogeneity among studies was explored using the chi-square based on Q statistic test. If P \> 0.1 or *I*^2^ \< 50%, fixed effects model was used to calculate the pooled OR/HR. Otherwise, random-effects model was used \[[@R61]\]. Sensitivity analysis was also conducted to evaluate stabilities of pooling results by omitting studies that brought heterogeneity or publication bias. Potential publication bias was checked by Begg\'s funnel plots and Egger\'s test \[[@R62], [@R63]\].
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